Stock News & Analysis

Black liquidated half her direct equity stake following a 329% one-year stock surge, retaining roughly $3.3 million in holdings.

A 10x return sounds like hype until you hear the actual milestones the CEO says are needed to get the stock there.

SpaceX is now the largest single stock holding in the university endowment fund.

After shares fell 12% in the last four years, the bulls hope that the rest of the decade will be better.

These healthcare companies can actually benefit from inflation.

XBI's lower fees and 155-stock portfolio contrast sharply with FBT's concentrated 30-holding approach, though FBT has experienced less volatility over the past five years.

Investors must weigh the upside in these chip stocks against risks and volatility.

This Amex card earns 3% cash back on groceries, gas, and online shopping with no annual fee -- plus it has a solid welcome bonus offer. Here's what to know.

Enbridge has been a very reliable dividend stock.

Cerebras unveils faster AI chip, OpenAI's losses widen, and more...

One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost.

This single data point is also crucial to the company's long-term investment thesis.

After its IPO, X-Energy's shares are up nearly 20% so far this month. Will they crush Oklo's?

One of the fastest-growing businesses inside the company more than doubled over the past year. What does five more years of that do to a $2.8 trillion valuation?

Maxing out a Roth IRA in your 30s can build a seven-figure, tax-free retirement fund, thanks to decades of compound growth.

Insider divested 11% of holdings as stock declined 30% over past year, reducing direct ownership to 164,904 shares valued at $20.11 million.

If you're 65, you're well into standard retirement age, but you shouldn't rush into claiming Social Security without knowing a few key facts.

The upstart chipmaker recently reported strong second-quarter revenue growth and issued an upbeat outlook.

Ken Griffin sees a bargain in Abbvie and increased his fund's position by buying 2.68 million shares of the healthcare giant.

The business continues to perform well, although this hasn't prevented the shares from falling 14% in 2026.